CGL
NMRA icon

Clarius Group LLC’s Neumora Therapeutics NMRA Stock Holding History

Clarius Group LLC’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$30.4K Hold
16,992
– – ﹤0.01% 384
2025
Q3 		$30.9K Hold
16,992
– – ﹤0.01% 398
2025
Q2 		$12.5K Hold
16,992
– – ﹤0.01% 480
2025
Q1 		$17K Hold
16,992
– – ﹤0.01% 481
2024
Q4 		$180K Hold
16,992
– – 0.01% 435
2024
Q3 		$224K Buy
+16,992
New +$198K 0.02% 397

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Clarius Group LLC's NMRA Position: Q4 2025 in Review

Clarius Group LLC held its Neumora Therapeutics (NMRA) position steady in Q4 2025 at 16,992 shares worth $30.4K. The position accounts for ﹤0.01% of the portfolio, ranked #384.

Clarius Group LLC first reported a position in NMRA in Q3 2024 and has held it in 6 quarters since. The position peaked at $224K in Q3 2024. 102 funds tracked by Wall St. Rank hold NMRA as of Q4 2025.

  • Clarius Group LLC held 16,992 shares of Neumora Therapeutics worth $30.4K as of Q4 2025.
  • Clarius Group LLC left its Neumora Therapeutics share count unchanged in Q4 2025.
  • Neumora Therapeutics made up ﹤0.01% of Clarius Group LLC's portfolio in Q4 2025, its #384 holding.
  • Clarius Group LLC first reported a position in Neumora Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Clarius Group LLC's Neumora Therapeutics position peaked at $224K in Q3 2024.
  • 102 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2025.

Based on Clarius Group LLC's 13F filing for Q4 2025, filed 14 Jan 2026.